GlassScriptPhysician profile
Lourdes Perez
NPI 1841845484
$8,527.83
in general payments reported to CMS, 2019-2025
59 companies · $2,389 in 2025
The $2,389 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $796 · 2022: $1,580 · 2023: $1,346 · 2024: $2,417 · 2025: $2,389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,218 · Long Term Medical Supply Or Device Loan: $848 · Education: $85.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,217.77 |
| Long Term Medical Supply Or Device Loan | $848.19 |
| Education | $85.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,311.38 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $862.74 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Janssen Biotech, INC. | $817.70 | 2021-2025 | Erleada, Darzalex, Imbruvica |
| Merck Sharp & Dohme LLC | $611.33 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $535.65 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $457.02 | 2022-2025 | Opdivo, Krazati |
| Daiichi Sankyo INC. | $405.35 | 2022-2025 | Enhertu, Datroway |
| Lilly USA, LLC | $256.48 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $242.92 | 2023-2025 | Alunbrig, Ninlaro, Iclusig |
| Incyte Corporation | $196.06 | 2021-2025 | Jakafi |
| Genzyme Corporation | $179.33 | 2021-2025 | |
| Amgen INC. | $164.80 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $129.67 | 2022-2023 | Tukysa |
| Regeneron Healthcare Solutions, INC. | $127.81 | 2022-2025 | Libtayo, Lynozyfic |
| G1 Therapeutics, INC. | $117.91 | 2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirati Therapeutics, INC. | $96.42 | 2023-2024 | Krazati |
| Pharmaessentia USA Corporation | $88.71 | 2022-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $85.83 | 2025 | Ultomiris |
| Emd Serono, INC. | $84.78 | 2022-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $81.74 | 2023-2024 | |
| Tempus Ai, INC | $80.69 | 2024-2025 | Xt Cdx |
| Beigene USA, INC. | $80.50 | 2022-2024 | Brukinsa |
| Eisai INC. | $80.26 | 2021-2025 | |
| Abbvie INC. | $75.82 | 2024-2025 | |
| Stemline Therapeutics INC. | $73.47 | 2023-2025 | Orserdu |
| Astellas Pharma US INC | $70.60 | 2023-2025 | Padcev, Xtandi |
| Ipsen Biopharmaceuticals, INC | $70.27 | 2021-2024 | Onivyde |
| Array Biopharma INC | $69.53 | 2021-2025 | Xalkori, Lorbrena, Braftovi |
| Sobi, INC | $65.13 | 2023-2024 | |
| Myriad Genetic Laboratories, INC. | $58.20 | 2023-2024 | Myrisk |
| Beone Medicines USA, INC. | $57.88 | 2025 | Tevimbra |
| Celgene Corporation | $53.66 | 2022 | |
| Pharmacosmos Therapeutics INC. | $46.92 | 2023-2024 | Monoferric |
| Deciphera Pharmaceuticals INC. | $46.76 | 2023 | Qinlock |
| Sun Pharmaceutical Industries INC. | $45.92 | 2024 | |
| Jazz Pharmaceuticals INC. | $45.19 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.93 | 2021 | |
| Genentech USA, INC. | $44.85 | 2023-2025 | Venclexta, Erivedge |
| Janssen Pharmaceuticals, INC | $44.31 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $39.97 | 2024-2025 | Pyrukynd |
| Tersera Therapeutics LLC | $37.07 | 2023-2025 | Zoladex |
| Tolmar, INC. | $36.14 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $36.14 | 2025 | Rubraca |
| Coherus Oncology, INC. | $35.00 | 2023 | |
| Clovis Oncology, INC. | $27.99 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $27.49 | 2022 | |
| Myovant Sciences INC. | $25.35 | 2022 | |
| Glaxosmithkline, LLC. | $25.00 | 2025 | Ojjaara |
| Epizyme, INC. | $24.92 | 2022 | |
| Geron Corporation | $22.87 | 2025 | Rytelo |
| Taiho Oncology, INC. | $22.87 | 2024 | |
| Amneal Pharmaceuticals LLC | $21.98 | 2024 | Neulasta, Neupogen, Avastin |
| Springworks Therapeutics, INC. | $21.94 | 2025 | Ogsiveo |
| Blue Earth Diagnostics | $20.92 | 2022 | |
| Blueprint Medicines Corporation | $20.84 | 2023 | Ayvakit |
| Novocure INC. | $20.01 | 2025 | Optune Lua (Novottf-200t) |
| Organon LLC | $19.57 | 2022 | |
| Gilead Sciences, INC. | $17.17 | 2022 | |
| Puma Biotechnology, INC. | $16.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lourdes Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.